DiaMedica Therapeutics
DMAC
23 hedge funds and large institutions have $21M invested in DiaMedica Therapeutics in 2020 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
155% more capital invested
Capital invested by funds: $8.24M → $21M (+$12.8M)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
5% more funds holding
Funds holding: 22 → 23 (+1)
0.74% more ownership
Funds ownership: 20.72% → 21.46% (+0.74%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$898K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$372K |
| 3 |
Renaissance Technologies
New York
|
+$352K |
| 4 |
Bank of New York Mellon
New York
|
+$60.1K |
| 5 |
BlackRock
New York
|
+$27.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$700K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$296K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$35.3K |
| 4 |
Millennium Management
New York
|
-$30K |
| 5 |
PFGIA
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| – | +$36 | +8 | New |
|
DMAC Hedge Fund Activity: Q2 2020 in Review
23 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q2 2020, worth a combined $21M — up 155% from $8.24M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new DMAC positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Corriente Advisors, opening a new position worth an estimated $898K. The largest seller was Stonepine Capital Management, cutting an estimated $700K.
- 23 institutional investors held DiaMedica Therapeutics (DMAC) as of Q2 2020, up from 22 in Q1 2020.
- Funds reported $21M of DiaMedica Therapeutics stock for Q2 2020, up 155% quarter-over-quarter.
- 5 funds opened new DiaMedica Therapeutics positions in Q2 2020 and 4 closed out, a net change of +1 holder.
- The largest DiaMedica Therapeutics buyer in Q2 2020 was Corriente Advisors, an estimated $898K added.
- The largest DiaMedica Therapeutics seller in Q2 2020 was Stonepine Capital Management, an estimated $700K sold.
Based on aggregated 13F filings for Q2 2020.